Biohaven Ltd. (NYSE:BHVN) Receives $63.00 Average Price Target from Brokerages

Shares of Biohaven Ltd. (NYSE:BHVN - Get Free Report) have been assigned an average rating of "Buy" from the fourteen analysts that are presently covering the company, Marketbeat reports. Thirteen investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $63.00.

A number of research firms have issued reports on BHVN. Cantor Fitzgerald reiterated an "overweight" rating on shares of Biohaven in a research note on Tuesday, December 17th. Jefferies Financial Group started coverage on shares of Biohaven in a research note on Monday, September 16th. They issued a "buy" rating and a $57.00 price objective for the company. William Blair raised shares of Biohaven to a "strong-buy" rating in a research report on Friday, August 30th. HC Wainwright reiterated a "buy" rating and set a $59.00 target price on shares of Biohaven in a research note on Tuesday, December 17th. Finally, Robert W. Baird boosted their price target on shares of Biohaven from $58.00 to $60.00 and gave the stock an "outperform" rating in a report on Monday, September 23rd.

Biohaven Stock Performance

NYSE:BHVN traded up $0.24 during mid-day trading on Friday, reaching $36.66. 1,214,246 shares of the company's stock were exchanged, compared to its average volume of 1,125,383. The firm has a market capitalization of $3.71 billion, a PE ratio of -3.92 and a beta of 1.24. Biohaven has a one year low of $26.80 and a one year high of $62.21. The business's fifty day simple moving average is $45.96 and its two-hundred day simple moving average is $41.89.

Biohaven (NYSE:BHVN - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.70) earnings per share for the quarter, missing analysts' consensus estimates of ($1.67) by ($0.03). As a group, equities research analysts forecast that Biohaven will post -8.85 EPS for the current year.

Insider Activity at Biohaven

In other Biohaven news, Director John W. Childs bought 21,052 shares of Biohaven stock in a transaction that occurred on Wednesday, October 2nd. The shares were bought at an average price of $47.50 per share, with a total value of $999,970.00. Following the acquisition, the director now owns 21,052 shares in the company, valued at approximately $999,970. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 16.00% of the stock is owned by insiders.

Institutional Investors Weigh In On Biohaven

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. nVerses Capital LLC bought a new stake in shares of Biohaven during the third quarter valued at approximately $50,000. Redwood Wealth Management Group LLC bought a new stake in Biohaven in the 2nd quarter worth approximately $61,000. Values First Advisors Inc. bought a new position in Biohaven in the third quarter valued at about $78,000. US Bancorp DE boosted its holdings in shares of Biohaven by 57.1% in the third quarter. US Bancorp DE now owns 2,173 shares of the company's stock worth $109,000 after buying an additional 790 shares during the last quarter. Finally, KBC Group NV grew its position in shares of Biohaven by 24.5% during the 3rd quarter. KBC Group NV now owns 2,250 shares of the company's stock valued at $112,000 after acquiring an additional 443 shares during the period. 88.78% of the stock is currently owned by institutional investors.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.